Knowing how viruses change in the initial weeks of an infection can provide important information about their adaptability.
Acurx (ACXP) Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA communications. Acurx’s Executive Chairman, Bob DeLuccia, ...
STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results